- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 413826, 8 pages
Regulation and Prognostic Relevance of Symmetric Dimethylarginine Serum Concentrations in Critical Illness and Sepsis
1Department of Medicine III, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
2Institute of Clinical Chemistry and Pathobiochemistry, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
Received 23 April 2013; Revised 3 June 2013; Accepted 10 June 2013
Academic Editor: Jesús F. Bermejo-Martin
Copyright © 2013 Alexander Koch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. De Backer, J. Creteur, J.-C. Preiser, M.-J. Dubois, and J.-L. Vincent, “Microvascular blood flow is altered in patients with sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 166, no. 1, pp. 98–104, 2002.
- D. De Backer, K. Donadello, Y. Sakr et al., “Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome,” Critical Care Medicine, vol. 41, pp. 791–799, 2013.
- A. Donati, R. Domizi, E. Damiani, E. Adrario, P. Pelaia, and C. Ince, “From macrohemodynamic to the microcirculation,” Critical Care Research and Practice, vol. 2013, Article ID 892710, 8 pages, 2013.
- G. Hernandez, A. Bruhn, and C. Ince, “Microcirculation in sepsis: new perspectives,” Current Vascular Pharmacology, vol. 11, pp. 161–169, 2013.
- S. Skibsted, A. E. Jones, M. A. Puskarich et al., “Biomarkers of endothelial cell activation in early sepsis,” Shock, vol. 39, pp. 427–432, 2013.
- D. W. Landry and J. A. Oliver, “The pathogenesis of vasodilatory shock,” New England Journal of Medicine, vol. 345, no. 8, pp. 588–595, 2001.
- J. S. Davis, C. J. Darcy, T. W. Yeo et al., “Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis,” PLoS ONE, vol. 6, no. 2, Article ID e17260, 2011.
- G. Iapichino, M. Umbrello, M. Albicini et al., “Time course of endogenous nitric oxide inhibitors in severe sepsis in humans,” Minerva Anestesiologica, vol. 76, no. 5, pp. 325–333, 2010.
- R. J. Nijveldt, T. Teerlink, B. Van Der Hoven et al., “Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality,” Clinical Nutrition, vol. 22, no. 1, pp. 23–30, 2003.
- M. J. O'Dwyer, F. Dempsey, V. Crowley, D. P. Kelleher, R. McManus, and T. Ryan, “Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study,” Critical Care, vol. 10, no. 5, article R139, 2006.
- A. Koch, R. Weiskirchen, and J. Kunze, “Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients,” Journal of Critical Care. In press.
- A. A. Mangoni, “Chapter 3 the emerging role of symmetric dimethylarginine in vascular disease,” Advances in Clinical Chemistry, vol. 48, pp. 73–94, 2009.
- J. Leiper and P. Vallance, “Biological significance of endogenous methylarginines that inhibit nitric oxide synthases,” Cardiovascular Research, vol. 43, no. 3, pp. 542–548, 1999.
- E. Schwedhelm and R. H. Böger, “The role of asymmetric and symmetric dimethylarginines in renal disease,” Nature Reviews Nephrology, vol. 7, no. 5, pp. 275–285, 2011.
- S. M. Bode-Böger, F. Scalera, J. T. Kielstein et al., “Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease,” Journal of the American Society of Nephrology, vol. 17, no. 4, pp. 1128–1134, 2006.
- A. Koch, O. A. Gressner, E. Sanson, F. Tacke, and C. Trautwein, “Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients,” Critical Care, vol. 13, no. 3, article R95, 2009.
- A. Koch, E. Sanson, A. Helm, S. Voigt, C. Trautwein, and F. Tacke, “Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis,” Critical Care, vol. 14, no. 3, article R94, 2010.
- A. Koch, R. Weiskirchen, H. W. Zimmermann, E. Sanson, C. Trautwein, and F. Tacke, “Relevance of serum leptin and leptin-receptor concentrations in critically ill patients,” Mediators of Inflammation, vol. 2010, Article ID 473540, 9 pages, 2010.
- A. Koch, S. Voigt, C. Kruschinski et al., “Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients,” Critical Care, vol. 15, no. 1, article R63, 2011.
- Y. Backes, K. F. van der Sluijs, D. P. Mackie et al., “Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review,” Intensive Care Medicine, vol. 38, pp. 1418–1428, 2012.
- R. H. Böger, “Live and let die: asymmetric dimethylarginine and septic shock,” Critical Care, vol. 10, no. 6, article 169, 2006.
- J. T. Kielstein, R. H. Böger, S. M. Bode-Böger et al., “Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 594–600, 1999.
- T. Ogawa, M. Kimoto, H. Watanabe, and K. Sasaoka, “Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats,” Archives of Biochemistry and Biophysics, vol. 252, no. 2, pp. 526–537, 1987.
- S. Kiechl, T. Lee, P. Santer et al., “Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population,” Atherosclerosis, vol. 205, no. 1, pp. 261–265, 2009.
- J. Leiper, M. Nandi, B. Torondel et al., “Disruption of methylarginine metabolism impairs vascular homeostasis,” Nature Medicine, vol. 13, no. 2, pp. 198–203, 2007.